AI
AIDX
20/20 Biolabs, Inc.
$0.9600
+11.63%
$10.2M
No data for this timeframe.
Vol
Market Cap$10.2M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$527.6K
SEC Reports5
Press Releases2
Recent Activity
May 27, 2026
other
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to
May 26, 2026
SEC
20/20 Biolabs, Inc. filed an 8-K reporting that its Board adopted Amendment No. 1 to the Bylaws, reducing the stockholde
8-K — Impact 2/10
May 20, 2026
SEC
20/20 Biolabs reported Q1 2026 revenue of $0.4M, down 36% YoY and 55% below consensus, with EPS of -$0.28 vs. -$0.10 exp
8-K — Impact 6/10
May 20, 2026
SEC
20/20 BioLabs reported Q1 2026 revenue of $0.4M (down 36% YoY), missing consensus of $0.8M, and EPS of -$0.28 versus -$0
PRESS-RELEASE — Impact 6/10
Apr 2, 2026
Insider
Bergman Alan B. was granted 100,000 shares
Chief Financial Officer
Apr 2, 2026
Insider
Zhou Jiming was granted 150,000 shares
Chief Operating Officer
Mar 27, 2026
Press
20/20 Biolabs announced that 18 Maryland fire departments will receive over $520,000 in state funding to administer its
Impact 7/10
Mar 24, 2026
Press
20/20 Biolabs (AIDX) announced an exclusive U.S. technology license and access agreement with ROKIT Healthcare to integr
Impact 5/10
Price Targets
$5.00
+419.4% upside
Strong Buy
Current $0.9626
Low $5.00
Median $5.00
High $5.00
1 analysts
$5.00
$5.00
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 | $-0.12 — $-0.12 | 1 | |
| Next Q | $-0.06 | $-0.06 — $-0.06 | 1 | |
| Current FY | $-0.42 | $-0.42 — $-0.42 | 45% YoY | 1 |
| Next FY | $-0.38 | $-0.38 — $-0.38 | 10% YoY | 1 |
Latest Reports
NEUTRAL
8-K
2/10
20/20 Biolabs, Inc. filed an 8-K reporting that its Board adopted Amendment No. 1 to the Bylaws, reducing the stockholde
May 26, 2026
BEARISH
8-K
6/10
20/20 Biolabs reported Q1 2026 revenue of $0.4M, down 36% YoY and 55% below consensus, with EPS of -$0.28 vs. -$0.10 exp
May 20, 2026
BULLISH
Press
7/10
20/20 Biolabs announced that 18 Maryland fire departments will receive over $520,000 in state funding to administer its
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Cresset Asset Management, LLC | $497.0K | — |
| CITADEL ADVISORS LLC | $30.5K | — |
| Allworth Financial LP | $57.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | Bergman Alan | A | $0.00 |
| Apr 2, 2026 | Zhou Jiming | A | $0.00 |
| Mar 3, 2026 | Cohen Jonathan | A | $0.00 |
| Feb 19, 2026 | Rollins John | C | $0.00 |
| Feb 19, 2026 | Rollins John | C | $0.00 |
3 institutional holders with $527.6K total value (280,625 shares) as of 2026-Q1. Top holders: Cresset, CITADEL, Allworth.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Cresset Asset Management, LLC | 264,368 | $497.0K | 94.2% | — |
| 2 | CITADEL ADVISORS LLC | 16,227 | $30.5K | 5.8% | — |
| 3 | Allworth Financial LP | 30 | $57.00 | 0.0% | — |
7 unique insiders with 12 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Bergman Alan B. | Chief Financial Officer | AWARD | 100,000 | — | — |
| Apr 2, 2026 | Zhou Jiming | Chief Operating Officer | AWARD | 150,000 | — | — |
| Mar 3, 2026 | Cohen Jonathan M | Chief Executive Officer | AWARD | 352,936 | — | — |
| Feb 19, 2026 | Rollins John Woodson | Director | CONVERT | 13,029 | — | — |
| Feb 19, 2026 | Rollins John Woodson | Director | CONVERT | 13,029 | — | — |
| Feb 19, 2026 | Rollins John Woodson | Director | CONVERT | 6,135 | — | — |
| Feb 19, 2026 | Ross Michael A. | Director | CONVERT | 31 | — | — |
| Feb 19, 2026 | Ross Michael A. | Director | CONVERT | 31 | — | — |
| Feb 19, 2026 | Compton John G. | Director | CONVERT | 7,669 | — | — |
| Feb 19, 2026 | Compton John G. | Director | CONVERT | 7,669 | — | — |
| Feb 19, 2026 | COHEN RICHARD M | Director | CONVERT | 7,700 | — | — |
| Feb 19, 2026 | COHEN RICHARD M | Director | CONVERT | 7,700 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.2/10.
NEUTRAL
8-K
2/10
20/20 Biolabs, Inc. filed an 8-K reporting that its Board adopted Amendment No. 1 to the Bylaws, red
May 26, 2026
BEARISH
8-K
6/10
20/20 Biolabs reported Q1 2026 revenue of $0.4M, down 36% YoY and 55% below consensus, with EPS of -
May 20, 2026
BEARISH
PRESS-RELEASE
6/10
20/20 BioLabs reported Q1 2026 revenue of $0.4M (down 36% YoY), missing consensus of $0.8M, and EPS
May 20, 2026
BEARISH
8-K
6/10
20/20 Biolabs amended outstanding warrants with Streeterville Capital to reduce the exercise price f
Apr 28, 2026
NEUTRAL
EFFECT
6/10
20/20 Biolabs, Inc. (AIDX) has officially gone public via a direct listing, with its S-1 registratio
Apr 13, 2026
Analyst Price Targets
$5.00 mean target
+419.4% upside
Strong Buy (3.00)
$5.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9626 |
| Target Low | $5.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $5.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.12 | $-0.12 | — | — | — | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.06 | $-0.06 | $-0.06 | — | — | — | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.42 | $-0.42 | $-0.42 | 44.7% | — | — | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$-0.38 | $-0.38 | $-0.38 | 9.5% | — | — | $0.0B | 95.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.110 | -0.010 |
| 30d ago | $0.000 | -0.120 |
| 60d ago | $0.000 | -0.120 |
| 90d ago | $0.000 | -0.120 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Maxim Group | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
May 22, 2026
other
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
May 20, 2026
earnings
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
May 14, 2026
other
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
May 12, 2026
other
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
Apr 7, 2026
other
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
Mar 31, 2026
earnings
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
Mar 27, 2026
contract
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 0/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
Mar 24, 2026
contract
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare
Mar 12, 2026
other
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Feb 24, 2026
short_interest
FTD: AIDX — 137,317 shares ($1.4M) failed to deliver
Settlement: 20260224, Price: $10.33, FTD Value: $1,418,484.61, 20/20 BIOLABS INC COM ACCD INV